Original article
Modulation of transglutaminase activity in mononuclear phagocytes and macrophage-like tumor cell lines by differentiation agents

https://doi.org/10.1016/0014-4827(87)90413-7Get rights and content

Abstract

The effect of glucocorticosteroids, retinoids, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the tumor promoter phorbol myristate acetate (TPA) on the expression of transglutaminase activity in in vitro differentiating bone marrow-derived mouse and rat mononuclear phagocytes (BMDMP) and mouse and human myeloid leukemia cell lines was assessed. Dexamethasone was found to induce an increase of about 100% in transglutaminase activity in mouse and rat BMDMP. The effect was time- and dose-dependent, and specific for steroids with glucocorticoid activity. Retinoic acid (RA) suppressed transglutaminase activity in mouse BMDMP (~50%) and enhanced it in rat BMDMP (100–200%). Other retinoids were less effective. 1,25(OH)2D3 had little effect on transglutaminase expression in mouse BMDMP and suppressed it in rat BMDMP (~60%). TPA exerted a suppressive effect (~50%) on transglutaminase activity of both rat and mouse BMDMP.

In murine (P388D1 and J774.2) and human (ML3, HL-60, KG-1, HEL, U937) myeloid leukemia cell lines, dexamethasone enhanced transglutaminase activity to a varying degree (100–1000%), RA suppressed it in P388D1 cells (~70%) and enhanced it in the other cell lines (100–1500%), 1,25(OH)2D3 induced a rather small augmentation of enzyme expression, whereas TPA suppressed enzyme expression (70–100%).

The species-specific differences previously observed by us for the effect of RA, dexamethasone and 1,25(OH)2D3 on the formation of BMDMP from mouse and rat bone marrow progenitor cells are now shown to extend also to effects on expression of transglutaminase activity. From a mechanistic point of view it is of interest that dexamethasone uniformly enhanced transglutaminase activity, whereas TPA suppressed it. RA and 1,25(OH)2D3 induced either suppression or enhancement in the various cell types, with no correlation between the direction of the effect of the two agents. The data suggest that modulation of transglutaminase activity by the four agents occurs via disparate mechanisms.

References (34)

  • M.P. Murtaugh et al.

    J biol chem

    (1983)
  • R Kannagi et al.

    Biochem biophys res commun

    (1982)
  • P.J.A Davies et al.

    J biol chem

    (1985)
  • L Fesus et al.

    Mol immunol

    (1981)
  • R.W. Leu et al.

    Exp cell res

    (1982)
  • W.T. Moore et al.

    J biol chem

    (1984)
  • T.R. Breitman et al.

    Blood

    (1981)
  • M.M. Bradford

    Anal biochem

    (1976)
  • U Danesch et al.

    J biol chem

    (1983)
  • S Shull et al.

    J biol chem

    (1983)
  • D Douer et al.

    Exp cell res

    (1982)
  • R Lotan

    Biochim biophys acta

    (1980)
  • P.J. Birckbichler et al.

    Ann NY acad sci

    (1978)
  • M.E. Folk

    Annu rev biochem

    (1980)
  • M.P. Murtaugh et al.

    J exp med

    (1984)
  • G. Schroff et al.

    Eur j immunol

    (1981)
  • K-H.L. Hsu et al.

    J natl cancer inst

    (1983)
  • Cited by (10)

    • The synergistic role of Pu.1 and Fms in zebrafish osteoclast-reducing osteopetrosis and possible therapeutic strategies

      2020, Journal of Genetics and Genomics
      Citation Excerpt :

      Thus, these osteopetrosis animal models may provide chances for therapeutic osteopetrosis drug development. RA, a commonly used clinical drug for acute promyelocytic leukemia (Huang et al., 1988), has been reported to promote osteoclast proliferation and differentiation (Goldman, 1987; Kaji et al., 1995; Jeradi and Hammerschmidt, 2016). Thus, we wanted to know whether RA could activate osteoclasts and rescue osteopetrosis in pu.1G242D and fmsj4e1 zebrafish models.

    View all citing articles on Scopus

    The work was supported in part by the Edward D. and Anna Mitchell Research Fund.

    View full text